Cargando…
LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
BACKGROUND: LCL161, a novel Smac mimetic, is known to have anti-tumor activity and improve chemosensitivity in various cancers. However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small cell lung cancer (NSCLC) remain unknown. METHODS: Cellular inhibitor of apopto...
Autores principales: | Yang, Chengcheng, Wang, Huangzhen, Zhang, Boxiang, Chen, Yimeng, Zhang, Yamin, Sun, Xin, Xiao, Guodong, Nan, Kejun, Ren, Hong, Qin, Sida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062899/ https://www.ncbi.nlm.nih.gov/pubmed/27737687 http://dx.doi.org/10.1186/s13046-016-0435-7 |
Ejemplares similares
-
Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
por: Darding, M, et al.
Publicado: (2011) -
Cytoplasmic and Nuclear Functions of cIAP1
por: Zadoroznyj, Aymeric, et al.
Publicado: (2022) -
Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation
por: Gill, Catherine, et al.
Publicado: (2009) -
Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization
por: Morón-Calvente, Virginia, et al.
Publicado: (2018) -
Expression and Correlation of Cell-Free cIAP-1 and cIAP-2 mRNA in Breast Cancer Patients: A Study from India
por: Verma, Amit Kumar, et al.
Publicado: (2020)